OR
Oruka Therapeutics, Inc.
ORKA · NASDAQ
$93.38 -1.90% (-$1.81)
1M -7.28%
Market Cap $5.90B
P/E Ratio -
Div. Yield -
ROE 20.76%
Piotroski F-Score Weak
2/9Valuation
34 /100
Fair P/B 5.29x
P/FCF N/A
P/S N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 11.66%
ROIC 13.88%
Debt
100 /100
Low Current ratio 38.51x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
50 /100
Moderate Beta -0.39x
EPS volatility N/A
Profitable years N/A
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na ORKA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lawrence Otto Klein
Employees
68
Headquarters
Menlo Park
Nadcházející události
11 LIS
Earnings
Upcoming earnings report